Pharmacist Biosimilars | Oncology Written 1h

Biologic therapies are essential in oncology care, yet their complexity presents unique challenges in practice. This course examines the science and regulation of biosimilars, the FDA approval and interchangeability process, and the evidence supporting their safety and effectiveness. Learners will develop strategies to incorporate biosimilars into oncology practice through informed substitution, patient communication, and collaboration with the healthcare team.

Learning Objectives

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Define key terminology related to biosimilar products.
2. Explain the FDA’s process for developing, reviewing, and approving biosimilars.
3. Assess the impact of biosimilars on patients, payers, providers, and pharmacies in hematology/oncology practice.
4. Discuss the potential effects of an interchangeability designation for a biosimilar.
5. Develop a collaborative process for pharmacy team members to be more involved in substituting biosimilars.

Faculty

Kelly Brunk, PharmD, BCOP, MBA

Senior Manager of Clinical Excellence
NCODA

Disclosures:

Kelly Brunk was a speaker and served on the advisory board for Pfizer (ended May 2024). All relevant financial relationships have been mitigated.

Course Details